Clinical Trial Update: Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion [Phase 3]

View source ↗

Summary

Phase 3 trial update on DPI-386 nasal gel for prevention of nausea and vomiting due to motion; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Motion Sickness

Drugs mentioned

• DPI-386 (DPI-386)

Snippet

Sponsor: Repurposed Therapeutics, Inc. | Conditions: Motion Sickness | Phase 3 | Status: COMPLETED